First Trust Advisors LP Has $2.17 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX

First Trust Advisors LP lifted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 78.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 68,470 shares of the biopharmaceutical company’s stock after purchasing an additional 30,157 shares during the quarter. First Trust Advisors LP owned 0.09% of Celldex Therapeutics worth $2,172,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its stake in Celldex Therapeutics by 62.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,059,534 shares of the biopharmaceutical company’s stock worth $33,596,000 after buying an additional 407,818 shares during the period. AlphaCentric Advisors LLC bought a new position in Celldex Therapeutics during the first quarter worth about $400,000. Candriam S.C.A. bought a new position in Celldex Therapeutics during the first quarter worth about $8,846,000. Y Intercept Hong Kong Ltd acquired a new position in Celldex Therapeutics in the first quarter valued at about $1,433,000. Finally, Assenagon Asset Management S.A. acquired a new position in Celldex Therapeutics in the first quarter valued at about $4,648,000.

Celldex Therapeutics Trading Up 0.4%

CLDX stock opened at $41.71 on Friday. The stock has a 50-day moving average price of $35.19 and a two-hundred day moving average price of $31.54. The stock has a market cap of $3.27 billion, a PE ratio of -9.59 and a beta of 0.87. Celldex Therapeutics, Inc. has a 1 year low of $19.72 and a 1 year high of $42.92.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.12. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.73 million. On average, analysts forecast that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CLDX has been the topic of a number of research analyst reports. Cantor Fitzgerald dropped their price target on Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 22nd. HC Wainwright reiterated a “buy” rating and issued a $42.00 price objective on shares of Celldex Therapeutics in a research report on Monday, June 15th. Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Friday, July 17th. Finally, UBS Group raised their target price on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $55.46.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.